Intrinsic asthma is a form of asthma that develops without any identifiable allergic trigger. Unlike the more common allergic (extrinsic) type, it isn’t driven by reactions to pollen, dust mites, or pet dander. It typically appears later in life, with a median age of diagnosis around 49, and it accounts for roughly 57% of adult asthma cases. Because it doesn’t follow the familiar allergy pattern, it can be harder to diagnose and often more difficult to treat.
How It Differs From Allergic Asthma
The classic distinction comes down to what sets off the immune system. In allergic asthma, your body produces IgE antibodies in response to specific allergens like pollen or mold. Skin prick tests come back positive, and there’s often a family history of allergies or hay fever. Symptoms may flare seasonally or after known exposures.
Intrinsic asthma looks different on nearly every measure. Skin prick tests to common allergens are negative. There’s no seasonal pattern and no clear allergic family history. It tends to be more severe at diagnosis, with lung function often already below 80% of predicted values. It also shows a strong female predominance and a frequent association with nasal polyps, which are uncommon in allergic asthma. Francis Rackemann, the physician who first drew the distinction in the 1940s, described intrinsic asthma as a disease of later onset, greater severity, and closer ties to sinus disease.
Common Triggers
Without allergens driving the process, intrinsic asthma flares are set off by a different set of irritants. Respiratory viruses are one of the most potent triggers and a major cause of exacerbations. Cold air, exercise, tobacco smoke, and fine particulate matter (the tiny pollution particles known as PM2.5) are also well-established triggers.
Volatile organic compounds, or VOCs, play a larger role than many people realize. These are chemicals released by everyday products: perfumes, air fresheners, cleaning solutions, paints, and paint thinners. Specific compounds like limonene (common in citrus-scented products) have been linked to wheezing, while formaldehyde exposure is associated with worsening breathlessness and reduced lung function. Toluene, a hydrocarbon in paints and household cleaners, has also been implicated. For someone with intrinsic asthma, a freshly painted room or a heavily scented cleaning product can be enough to provoke symptoms.
What Happens in the Airways
Even without an allergic trigger, intrinsic asthma still involves significant airway inflammation. Immune cells called Th2 lymphocytes produce a cascade of signaling molecules, including interleukins (IL-4, IL-5, and IL-13), that recruit inflammatory cells and sustain the process. IL-5 in particular keeps eosinophils alive in the airway tissue, where they cause damage. IL-13 drives mucus overproduction and structural changes in the airway walls, a process called remodeling, where the airways gradually thicken and stiffen over time.
Some people with intrinsic asthma have a different inflammatory profile altogether, with neutrophils rather than eosinophils dominating the picture. This distinction matters because it affects which treatments work and which don’t.
Linked Conditions
Intrinsic asthma rarely exists in isolation. More than a third of people with severe asthma have chronic rhinosinusitis with nasal polyps, and this association is strongest in non-allergic patients. Nasal polyps, aspirin sensitivity, and late-onset asthma form a well-known triad. In one study of severe asthma patients, aspirin sensitivity carried an odds ratio of nearly 8 for severe disease, and the combination of aspirin sensitivity and nasal polyps was even more strongly linked.
If you have intrinsic asthma and notice progressive nasal congestion, loss of smell, or worsening symptoms after taking aspirin or ibuprofen, these overlapping conditions may be part of the picture. Chronic sinus inflammation and asthma share similar inflammatory pathways in the upper and lower airways, so treating one often helps the other.
Diagnosis
Identifying intrinsic asthma is partly a process of exclusion. Standard allergy testing, through skin prick tests or blood tests measuring allergen-specific IgE, comes back negative. Total IgE levels in the blood tend to be normal or low, unlike in allergic asthma where they’re elevated.
One useful diagnostic tool is fractional exhaled nitric oxide, or FeNO, a breath test that measures airway inflammation. Values above 50 parts per billion in adults are considered high and suggest eosinophilic inflammation, while values below 25 ppb suggest it’s less likely. Blood eosinophil counts add another piece: levels above 300 cells per microliter point toward eosinophil-driven disease. These biomarkers don’t just confirm inflammation; they help guide treatment decisions, particularly when biologic therapies are being considered.
Why Standard Treatment May Fall Short
Inhaled corticosteroids are the backbone of asthma treatment, but intrinsic asthma is more likely to resist them. One reason is molecular. Some people overproduce an inactive form of the glucocorticoid receptor (the protein that corticosteroids bind to), which competes with the active form and blocks the anti-inflammatory effect. Genetic variations and changes in how the receptor is chemically modified after it’s made can further impair its ability to do its job. This isn’t a matter of taking the wrong dose. The cells themselves are less capable of responding to the medication.
When inhaled corticosteroids aren’t enough, biologic therapies offer a more targeted approach. These are injectable medications designed to block specific inflammatory molecules. Anti-IL-5 biologics like mepolizumab and benralizumab target eosinophilic inflammation directly, reducing the survival and recruitment of eosinophils. Dupilumab blocks both IL-4 and IL-13, cutting down mucus production and airway remodeling. Clinical trials have shown the greatest benefit in patients with elevated FeNO (above 25 ppb) and higher blood eosinophil counts, which is why biomarker testing before starting these therapies is standard.
Newer approaches in development include JAK inhibitors, which target a different inflammatory signaling pathway, and drugs that restore the function of a key enzyme needed for corticosteroids to work properly. These are aimed specifically at people whose asthma doesn’t respond to current options.
Long-Term Outlook
Intrinsic asthma tends to follow a more aggressive course than its allergic counterpart. A 10-year follow-up study of 180 adults found that people with intrinsic asthma lost lung function at roughly 50 milliliters of FEV1 per year, compared to 22.5 milliliters per year in those with allergic asthma. That’s more than double the rate. The decline also accelerated with age in both groups, but the gap remained consistent.
Interestingly, the factors predicting worse outcomes differed between types. In intrinsic asthma, greater airway variability at diagnosis, meaning larger swings in lung function with bronchodilator use, predicted a steeper decline. In allergic asthma, the degree of baseline obstruction and need for corticosteroids were better predictors. This difference reinforces that the two forms of asthma aren’t just triggered differently; they behave differently over time.
The faster rate of decline makes consistent monitoring and early treatment escalation particularly important for people with intrinsic asthma. Regular spirometry, tracking of symptoms, and reassessment of the treatment plan can help slow the progression and preserve lung function over the long term.